You are here

A TRIPS waiver would jeopardise, not support, efforts to accelerate COVID-19 vaccine production globally

7 May 2021
All Committees
Intellectual Property

Global access to COVID-19 vaccines is critical for protecting the health of citizens around the world and ensuring a strong economic recovery. According to Airfinity data, industry is on track to produce 10 billion units of vaccine this year, with manufacturing capability set to increase even further. This is the largest ramp-up in the history of vaccine production. Intense collaboration between the public and private sectors and between companies, enabled by a stable intellectual property framework, has been an essential piece of this incredible success story in terms of research, manufacturing and distribution. Read more.

Vaccine production waiver